Ireland
--:--IST
Latest
Clinical Trials in France / NCT06338397
Recruiting Not applicable

Social & Affective Cognition in Alzheimer's Disease & Associated Disorders

NCT06338397 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-01-28
Last updated
2026-04-30

Condition(s) studied

Alzheimer's DiseaseFrontotemporal Degeneration (Semantic & Behavioral Variants)

Investigational drug(s) / intervention(s)

SCANN

SCANN: Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.

Study summary

Recent studies have shown that individual neuropsychological scores of patients with Alzheimer's disease and Associated Disorders (ADAD) are only poorly correlated to their behavioral difficulties, such as disinhibition, apathy, social decision-making or vulnerability. Recently, social \& affective cognitive disorders have been highlighted as potential cause of social behavioral abnormalities. However, no previous studies have assessed the specific relationship between social \& affective cognition \& social behavior in ADAD. Our pilot study aims to explore the correlations between core and extended social \& affective cognitive processes and social behavior as observed during the neuropsychological examination, as well as to explore the common brain regions involved in those domains.

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women; * 40 to 85 years of age (included); * Registered with the French Social Security; * Have a study partner. The study partner is required to complete several scales. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor. * Fluent in French, able to read and write; Exclusion Criteria: * Participants who have contraindications to perform an MRI scan; * Participants with significant sensory deficits that are not corrected by suitable devices. * Participants with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load, in the judgment of the investigator; * Participants with other neurodegenerative disease such as Lewy body dementia and Parkinson's disease; * Participants with other serious neurological disorder such as brain tumor, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study; * Participants with excessive alcohol intake or drug abuse, in the judgment of the investigator; * Participants who, in the opinion of the investigator, have a risk of non-compliance to the study procedures;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Lille University Hospital Lille France Recruiting

More University Hospital, Lille trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06338397 on ClinicalTrials.gov ↗ ← All trials in France